$CTSO

MARIANI PETER J purchased $44K of CTSO

MARIANI PETER J (Chief Financial Officer) purchased 100,000 shares of Cytosorbents Corp (CTSO) at $0.44 on 2026-06-15.

Original reporting
SEC EDGAR · MARIANI PETER J
Published Jun 16, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CTSO
Bullish
low confidence
Mentioned
$CTSO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSOBullishLow
01

Why it matters

The newest information is the CFO’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

This provides a fresh, primary-source datapoint on insider buying, which may slightly influence sentiment but does not change fundamentals on its own.

03

What to watch

The article provides no context on prior insider activity, total compensation, or whether the purchase is part of a broader pattern; traders should compare with recent Form 4 history.

Relevance 4/10Novelty 8/10Timing: filed 2026-06-16 (transaction dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for Cytosorbents Corp.

Company-level read

Ticker impact

$CTSOBullishLow confidence
Context

Cytosorbents CFO Peter J. Mariani filed an open-market purchase of 100,000 shares at $0.44 on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades.

Evidence & confidence

The disclosure is a Form 4 insider transaction with no accompanying operational, financial, or regulatory news; size is moderate and lacks a stated 10b5-1 plan.

Market effects

No clear sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may not reflect near-term business improvement; without a 10b5-1 plan, timing could be personal rather than informational.

Key entities

  • Cytosorbents Corp

    Subject of the SEC Form 4 insider transaction disclosure.

  • Peter J. Mariani

    Cytosorbents CFO who purchased 100,000 shares open-market.

Related articles

$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.